We studied the prognostic value of clinical and laboratory variables, measured before blood cell transplantation, in predicting complete response among patients undergoing autologous blood cell transplantation for relapsed or primary refractory myeloma. Sixty-seven patients who underwent transplantation for relapsed or primary refractory myeloma were studied. The overall response rate was 90%, and the complete response rate was 33%. Low ␤ 2 -microglobulin (р2.7 mg/l) was associated with a significantly better complete response rate compared with high levels (54 vs 19%, P = 0.002). Similarly, the complete response rate was 39% when the bone marrow plasma cell percentage was low (Ͻ40%) and 21% with greater involvement (P = 0.04). Complete response rate was 50% when ␤ 2 -microglobulin and bone marrow plasma cell percentage were low, 36% if either was high, and 12% when both were high (P = 0.01). Median survival measured from initial diagnosis of myeloma was 51 months. Overall survival after transplantation was better among responders who achieved complete response than those who did not: median survival, 24 vs 11 months, P = 0.04 (log-rank) and 0.009 (Gehan-Wilcoxon). Attainment of a complete response independently predicted better survival in a multivariate analysis. ␤ 2 -Microglobulin and bone marrow plasma cell percentage predict complete responders among patients undergoing transplantation for myeloma. Keywords: complete response; ␤ 2 -microglobulin; multiple myeloma; prognostic factors; transplantation Multiple myeloma is a clonal plasma cell proliferative disorder that accounts for 10% of all malignant hematologic neoplasms.
with regimens such as vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP). With these regimens, median survival is about 3 years. 4 Only 3% of patients live longer than 10 years. 5 High-dose chemotherapy, with or without total body irradiation, followed by blood cell transplantation is an alternative to conventional chemotherapy and appears to improve response rates and survival. [6] [7] [8] A randomized trial in previously untreated patients with myeloma showed improved survival with autologous marrow transplantation compared with conventional chemotherapy, with 5-year survival rates of 52% and 12%, respectively. 9 Many centers offer transplantation to newly diagnosed patients. However, it is possible that transplantation can be delayed until patients fail to respond to conventional chemotherapy if stem cells are harvested early in the disease course. With the latter approach, newly diagnosed patients are initially treated for a few months with chemotherapy that is not toxic to stem cells to minimize the tumor burden. Peripheral blood stem cells are then mobilized and cryopreserved for future use. Subsequently, patients continue conventional chemotherapy until relapse, at which point they are considered for transplantation.
Transplantation for myeloma is not curative. Almost all patients who have had transplants eventually relapse, and there is no plateau on the survival curves. 6 Achieving a complete response (CR) is an important goal of transplantation. 3 As a subset, patients achieving CR have superior overall and disease-free survival. 9 However, only 20-40% of patients undergoing transplantation achieve a CR. 9, 10 We studied the predictive value of clinical and laboratory variables measured immediately before transplantation in identifying patients who are likely to attain CR.
Patients and methods
Sixty-seven patients underwent high-dose therapy and blood cell transplantation for relapsed or primary refractory myeloma at the Mayo Clinic between June 1989 and August 1997 (47 men and 20 women, ages 33-67 years (median, 52 years) ). Data from transplant patients were collected prospectively and entered into a comprehensive computerized database. Information regarding response to therapy, relapse, and survival is updated continuously. The following clinical and laboratory variables measured immediately before transplantation were studied to determine ability to predict subsequent CR: age, sex, stage, ␤ 2 -microglobulin (␤ 2 M), response to prior therapy, type of monoclonal (M) protein, resistant disease at blood cell transplantation, time from diagnosis to transplantation, bone marrow plasma cell percentage at transplantation, number of prior chemotherapy regimens, slide-based plasma cell labeling index (PCLI), cytogenetic analysis, lactate dehydrogenase (LDH), and C-reactive protein.
Resistant disease was defined as progression of myeloma or failure to achieve a 50% or greater reduction in monoclonal protein level with the pretransplant standard-dose chemotherapy regimen.
No patients were lost to follow-up. All patients gave written informed consent for research bone marrow and blood samples to be taken and again before stem cell mobilization. Approval by the Mayo Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
Stem cells were harvested from most patients after initial chemotherapy with vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD). High-dose cyclophosphamide (3.0-4.5 g/m 2 over 1-2 days) followed by granulocyte colony-stimulating factor (G-CSF) was used as the priming regimen to collect peripheral blood stem cells in 34% of patients; G-CSF alone was used in the rest. All patients had relapsed disease during or after prior standard-dose chemotherapy or had primary chemorefractory disease. The conditioning regimen (high-dose therapy) consisted of melphalan 140 mg/m 2 and total body irradiation in 50 patients. Eleven patients received melphalan, cyclophosphamide, and total body irradiation (12 Gy total dose, administered in 2-3 Gy fractions per day for 3-4 days) and three received melphalan 200 mg/m 2 alone. Three patients received other regimens. All patients had stem cells reinfused after highdose therapy except for one patient (included in the analysis) who died of sepsis one day before stem cell infusion. Routine post-transplant maintenance with interferon was not administered. Fewer than five to 10 patients received such treatment, at the discretion of the treating physician.
After transplantation, CR was defined as lack of detectable M protein in serum and urine by immunoelectrophoresis and immunofixation. Because a bone marrow biopsy was not performed routinely to document CR, bone marrow plasma cells were not included in the definition of CR. No specific duration of CR was required to meet the definition. Objective response was defined as reduction of serum M protein and 24 h urinary light chain excretion by at least 50%, accompanied by a similar reduction of soft-tissue plasmacytomas if present. Patients with urine light chain required only a reduction of urinary light chain excretion to 10% or less of the pretreatment value. Relapse (or progression in the case of partial responders) after transplantation was defined as a 50% increase in the serum M protein or 24 h urinary M protein excretion over the lowest value in remission. In patients achieving a CR, any detectable M protein by immunofixation, even if nonmeasurable, constituted relapse. Patients suspected of relapse based on M protein determinations are further staged with physical examination, chemistry panels, and radiographic skeletal survey. Increase in the size of existing lytic bony lesions or softtissue plasmacytomas or appearance of new lytic bony lesions constituted relapse (or progression), even if not accompanied by changes in the M protein. Overall survival was measured from the date of transplantation to date of death or last follow-up. Progression-free survival (PFS) was defined as time from transplantation to relapse, disease progression, or death.
Bone marrow plasma cell percentage was obtained from the immunofluorescent PCLI studies done before transplantation. The PCLI is a reflection of the proliferative activity of the monoclonal plasma cells. [11] [12] [13] The assay can be done on bone marrow or peripheral blood and was performed using a slide-based immunofluorescence method on bone marrow samples, as described elsewhere. 11, 13 At least 500 cells staining positively for the same cytoplasmic light chain isotype as the patient's M protein are counted. PCLI is the percentage of such cells that show positive nuclear fluorescence for BU-1 antibody. A PCLI у1% is classified as high. The percentage of bone marrow cells that stain positively for the same cytoplasmic light chain isotype as the patient's M protein gives the bone marrow plasma cell percentage.
For cytogenetic analysis, bone marrow specimens were processed by both direct and short-term culture techniques, as described previously.
14,15 Serum ␤ 2 M levels were measured by an enzyme-linked immunosorbent assay.
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The 2 test was used to compare differences in the CR rate among the various subgroups. Survival analysis was done using the method described by Kaplan and Meier. 16 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test and the Gehan-Wilcoxon test. Multivariate analysis was done using Cox's proportional-hazards model. 17 Variables included in the multivariate analysis were age, sex, ␤ 2 M, LDH, Creactive protein, time to transplantation from initial diagnosis, response to prior chemotherapy, bone marrow plasma cell percentage, CR, PCLI, and bone marrow cytogenetics.
Results
Patient characteristics are listed in Table 1 . Patients underwent transplantation 5-88 months (median, 21 months) after the initial diagnosis of myeloma. At transplantation, all patients had relapsed or primary chemotherapy refractory disease. All had received prior chemotherapy, and 87% had received two or more regimens.
The serum M protein spike ranged from 0.0 to 10.4 g/dl (median, 2.0 g/dl) at transplantation. ␤ 2 M was Ͼ2.7 g/ml in 64% of patients, PCLI у1% in 49%, and bone marrow plasma cell percentage у40% in 43%. The median bone marrow plasma cell percentage was 34%.
Cytogenetic analysis
Twenty-eight of 62 patients (45%) had abnormal marrow cytogenetics and most abnormalities (93%) were complex (у3 abnormalities). This includes deletions of chromosomes 13 (46%) or 11 (25%) and translocations (29%). Abnormalities of chromosomes 13 or 11 or translocations were present in 89% of patients with cytogenetic abnormalities. Translocations were present in 29% of those with abnormal cytogenetics, including three patients who had translocations involving the immunoglobulin heavy chain region on chromosome 14.
Predictors of CR
The overall response rate after high-dose therapy and transplantation was 90%. CR occurred in 33% of patients. Table  2 lists the clinical and laboratory variables studied and their predictive value. In addition, factors such as age, sex, and time from diagnosis of myeloma to transplantation were studied and found not to predict CR. The overall response rate among patients with primary refractory disease, relapse on therapy (refractory relapse), and relapse off therapy was 82, 88 and 96%, respectively. The CR rate was 18, 31 and 39%, respectively. Although there was a trend toward inferior response rates among those with primary refractory disease, the differences were not statistically significant (P = 0.42 overall response and 0.47 CR).
␤ 2 M and bone marrow plasma cell percentage predicted CR (Table 2 ). Based on ␤ 2 M and bone marrow plasma cell percentage, we were able to identify three risk groups with differing CR rates. The CR rate was 50% when both ␤ 2 M and bone marrow plasma cell percentage were low (␤ 2 M Ͻ2.7 g/ml, bone marrow plasma cell percentage Ͻ40%, n = 22), 36% if either was high (n = 23), and 12% when both were high (n = 25) (P = 0.01).
In addition to ␤ 2 M and bone marrow plasma cell percent- 
Survival analysis
Forty-two patients have died. Recurrent myeloma was the cause of death in 32 patients. Seven patients died from transplant-related complications and one each from intracranial bleed, acute myeloid leukemia, and suicide. The median survival from the time myeloma was first diagnosed was 51 months. Median survival from the date of transplantation was 17 months for the cohort. PFS was 9 months. There was a trend toward shorter overall survival with high ␤ 2 M levels compared with low values (median survival, 12 vs 22 months, respectively), although the difference was not statistically significant (P = 0.21 log-rank). PFS was also not significantly different, with median times of 8 and 13 months, respectively (P = 0.11). Similarly, high bone marrow plasma cell percentage was associated with a nonsignificant trend toward shorter overall survival (11 months) compared with low values (21 months) (P = 0.12); PFS was not significantly different, with median times of 8 vs 10 months, respectively (P = 0.18).
Overall survival after blood cell transplantation was significantly longer in patients who achieved a CR compared with those who did not, with median survivals of 24 and 11 months, respectively (P = 0.04, log-rank, and 0.009, Gehan-Wilcoxon) (Figure 1a) . PFS also was significantly longer in patients achieving a CR, with median times of 14 and 8 months (P = 0.04, log-rank, and 0.01, GehanWilcoxon) (Figure 1b) . The same result was obtained when nonresponders were excluded and survival (overall survival and PFS) of those who attained CR was compared with partial responders.
In multivariate analysis, attaining CR was independent of all other factors studied, including cytogenetics, LDH, and PCLI in predicting overall survival (P = 0.02) and PFS (P = 0.02).
Apart from patients who achieved a CR, there were 13 patients who had a very good partial remission defined as a 90% or greater reduction in the M protein level. The overall and progression-free survival of these patients were identical to those of other partial responders who failed to achieve a CR, with median times of 11 and 8 months, respectively.
There were no differences in overall or progression-free survival between patients with chemotherapy-resistant disease and those with chemosensitive disease (P = 0.58 overall survival and 0.59 PFS). Similarly, the M protein type did not significantly affect overall survival (P = 0.26) or PFS (P = 0.13).
Discussion
Treatment for myeloma is not curative. The overall response rate with melphalan and prednisone is 40-60%, 4 the CR rate is less than 10%, and median survival is about 3 years. 18 Combination chemotherapy with regimens such as VBMCP leads to superior response rates (70%), but there is no survival benefit. 4, 19 Response rates with highdose therapy and transplantation exceed 75-90%, 4, 18 and CR rates range from 20% to 40%. 9, 10 Achievement of a CR is an important goal of transplantation. Hence, it is important to identify factors that predict complete responders among patients considering transplantation for myeloma. In our study, ␤ 2 M and bone marrow plasma cell percentage were associated with CR in patients undergoing high-dose therapy and blood cell transplantation for myeloma.
␤ 2 M is a small protein that forms the light chain of the human leukocyte antigen and has a molecular weight of 11 800. 20 It is a known predictor of survival in patients treated with conventional chemotherapy for myeloma.
11
Recent studies have identified ␤ 2 M as an independent predictor of overall and event-free survival after transplantation for myeloma. 21 In addition, there is an excellent correlation between serum ␤ 2 M levels and myeloma tumor burden. 22 It is not surprising that high levels of ␤ 2 M are associated with a low CR rate.
Similar to serum ␤ 2 M levels, bone marrow plasma cell percentage is an indicator of tumor burden. We used PCLI studies to determine the precise percentage of bone marrow plasma cell involvement. This method has the advantage of counting only bone marrow plasma cells that have the same cytoplasmic light chain isotype as the patient's M protein and hence may be a more accurate indicator of the extent of bone marrow involvement. This study showed that when bone marrow plasma cell involvement exceeded 40%, the probability of achieving a CR with present conditioning regimens decreased. Greater bone marrow involvement also is associated with greater contamination of the stem cell harvest with tumor cells. When both ␤ 2 M and bone marrow plasma cell percentage are high, the CR rate is only 12%. We also found that presence of an IgG monoclonal protein was associated with lower CR rates but had no impact on overall or progression-free survival.
Besides ␤ 2 M, other important predictors of survival in conventionally treated patients with myeloma are PCLI, age, LDH and C-reactive protein. 11, 23 Abnormal cytogenetics is an additional prognostic factor for overall survival and PFS in patients undergoing transplantation for myeloma. 21, 24, 25 In our study, factors such as cytogenetics and PCLI, which predict survival after transplantation, failed to predict complete responders. Tricot and colleagues 21 had similar results in a recent study of 427 patients for whom cytogenetics predicted survival but not CR rate. However, they found that a risk-based classification using ␤ 2 M, less than 12 months of prior therapy, and cytogenetics significantly predicted CR among patients undergoing transplan-tation for myeloma. These findings suggest that besides CR, other factors that govern the proliferative activity of plasma cells and early relapse also play an important role in outcome. We believe that it is important to consider prognostic factors for CR and for overall survival when considering transplantation for myeloma patients.
Primary chemotherapy-refractory patients may be poor candidates for transplantation. However, in our study these patients did not have a lower CR rate. Because a doseresponse relationship to chemotherapy is present in myeloma, patients who fail to respond to standard chemotherapy such as VAD may respond well to myeloablative regimens. 26, 27 High-dose therapy can cause significant reduction of tumor burden, including CRs, and is safe in patients with chemotherapy-resistant disease. 27, 28 We think such patients should not be excluded from consideration for transplantation.
The overall response rate of 90% and the CR rate of 33% that we report are similar to those reported in other studies. 10, 29 However, survival in our study (median, 17 months after transplantation) appears lower than that reported by others. 4, 21, 29 This is clearly the result of patient selection. All patients studied by us had refractory or relapsed disease at transplantation, and 87% had received two or more chemotherapy regimens before transplantation. More than 80% of the patients had Durie-Salmon stage III disease. Survival in our study is similar to a cohort of patients with advanced myeloma studied by Alexanian and colleagues. 30 Furthermore, preliminary data from a French randomized study indicate that there are no survival differences between patients undergoing early transplantation and those undergoing transplantation only at the time of relapse (delayed transplantation). 31 We found that complete responders have superior overall survival and PFS compared with those who failed to achieve a CR. To minimize the possibility that patients who attained a CR can show better survival solely because they live long enough to achieve such a result, we repeated the survival analysis after excluding all patients who failed to achieve a response. In such a comparison between patients who achieved a CR and those who achieved a partial response, patients attaining a CR still had superior overall survival and PFS.
In conclusion, from ␤ 2 M concentration and bone marrow plasma cell percentage, we can identify patients with relapsed or refractory myeloma who are unlikely to achieve a CR. These patients, as well as most other patients with myeloma, are candidates for clinical trials studying more effective conditioning regimens, 32 allogeneic bone marrow transplantation, 33 and other innovative post-transplant treatment approaches.
